In pancreatic cancer, the upregulation of Sestrin2 inhibited the cancer cells' migration, proliferation, and invasion by activating the p-Nrf2/KEAP1/HO-1/NQO-1 signaling axis 143. This evidence concerns the gene NFE2L2 and pancreatic neoplasm.